SAMSUNG BIOEPIS AND BIOGEN ANNOUNCE FDA FILING ACCEPTANCE OF SB11, A PROPOSED BIOSIMILAR REFERENCING LUCENTIS® (RANIBIZUMAB)
November 18, 2020 at 7:00 AM EST INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) — Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug...